




Ocular Implications of Mpox

Steven Yeh, MD, FASRS
Professor and Stanley Truhlsen Jr. Chair in Ophthalmology
Global Center for Health Security
Truhlsen Eye Institute, Univ. of Nebraska Medical Center
Adjunct Professor, Emory University School of Medicine

Jean-Claude Mwanza, MD, PhD, MPH
Professor of Ophthalmology
University of North Carolina at Chapel Hill
Dept of Ophthalmology, University of Kinshasa


WHO EPI-WIN Webinar 18 September 2024

The Eye as a Window to Emerging Infectious Diseases



Varkey et al NEJM 2015 Shantha et al Ophthalmol 2016

Ebola



Nguyen, Seitzman, Emerg Infect Dis 2023

Mpox



Uyeki et al NEJM 2024




Landmann 2021

Highly Pathogenic
Avian Influenza

Ophthalmic Implications of Mpox

Clinical Features

- Periocular, umbilicated lesions
- Blepharitis
- Conjunctivitis
- Keratitis (Epithelial and stromal)
- Uveitis, Hypopyon




Rodriguez et al J Infect Dis 2024






Uner et al Cornea 2023


Spectrum of Ocular Findings






Progression of epithelial keratitis

Doan et al *JAMA Ophthalmol 2023*



Superficial peripheral keratitis
Finamor et al *JAMA Ophthalmol 2022*




Corneal ulceration before and after treatment

Lamas-Francis et al Ocul Imm Inflamm 2024

Diagnostics and Molecular Detection


Isolated Ocular Mpox without Skin Lesions, United States



- · HIV-negative patient with scleritis, keratitis, and uveitis
- Mpox virus confirmed in sclera and cornea by PCR
- Deep sequencing showed Mpox RNA in aqueous humor

Nguyen et al Emerg Infect Dis 2023

Persistent ocular mpox infection in an immunocompetent individual



- Persistent mpox ocular involvement for 8 months
- Symptoms improved with tecovirimat and topical corticosteroid but recurred with withdrawal
- · Sx and infection resolved with tecovirimat and IV cidofovir

Raccagni et al Lancet Infect Dis 2023

Management Options and Preventive Measures

Systemic Treatment

Tecovirimat

Cidofovir

Brincidofovir

Vaccinia immunoglobulin IV (VIGIV)

Topical Therapies

Trifluridine 1%

Topical antibiotics (To prevent bacterial superinfection)

Ophthalmic lubrication

Kaufman et al. *JAMA Ophthalmol.* 2023;141(1):78-83

Cash-Goldwasser et al. *MMWR;* 71: 1343-1347.

Preventive Measures

Patient and Family

- Frequent handwashing, hand hygiene
- Avoidance of eye rubbing

Health Care Provider / Ophthalmologist

- IPC precautions and equipment disinfection protocols recommended (i.e., slit lamp biomicroscope, fundus exam)
- Source control (i.e., medical mask for patient)
- PPE: Gown, gloves, eye protection for front and sides of face, N95 respirator

www.cdc.gov

